Lundbeck partners with academia to advance understanding of Parkinson’s disease

15 May 2014

Danish CNS drug specialist Lundbeck (LUN: CO) says it is involved in new research with a UK university on Parkinson's disease, which may be the first step towards a new and significantly improved treatment of the debilitating disease.

At best, new treatments based on this new research could be on the market within 10 years, said Lundbeck, which currently has a number of research projects and collaborations relevant to Parkinson's disease.

In collaboration with researchers from the University of York, Lundbeck's researchers have made discoveries in fruit flies with regards to Parkinson's disease, which is a breakthrough in the understanding of the biological processes that occur in the brain in connection with the disease. The discoveries have just been published in the scientific journal, Human Molecular Genetics.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK